Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.

Timo Purmonen Soili TörmälehtoHanna WahlmanKari Puolakka

Published in: Journal of medical economics (2018)

Secukinumab is a cost-saving treatment option compared with adalimumab in the treatment of AS in Finland. More patients could be treated with a biologic by allocating resources more efficiently.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
end stage renal disease
newly diagnosed
chronic kidney disease
disease activity
juvenile idiopathic arthritis
prognostic factors